Licorice

drug
On this page

Also known as B2048FEMA NO. 2628FEMA NO. 2629FEMA NO. 2630Glycyrrhiza glabra extractGlycyrrhiza glabra rhizomeGlycyrrhiza glabra rootGlycyrrhiza glabra root powderGlycyrrhiza glabra root with rhizomeNDI 329

Summary

Licorice (CHEMBL2109060) is a phase-3 clinical-stage unknown; indicated across 6 conditions including dental caries and lichen planus, oral.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Indications: 6 conditions
  • Clinical trials: 11

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2109060
NameLicorice
TypeUnknown
Max phase3

Also known as: B2048, FEMA NO. 2628, FEMA NO. 2629, FEMA NO. 2630, Glycyrrhiza glabra extract, Glycyrrhiza glabra rhizome, Glycyrrhiza glabra root, Glycyrrhiza glabra root powder, Glycyrrhiza glabra root with rhizome, Licorice, NDI 329, LICORICE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
dental caries2MONDO:0005276EFO:0003819
lichen planus, oral2MONDO:0043923EFO:0008517
inborn error of immunity2MONDO:0003778HP:0002721
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
stroke disorder1MONDO:0005098EFO:0000712
mucositis1MONDO:0020579EFO:1001898

Clinical trials

Total trials: 11.

Phase distribution

PhaseTrials
Not specified7
PHASE41
PHASE2/PHASE31
PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00605202PHASE4COMPLETEDEffect of Licorice and Hydrochlorothiazide on Plasma Potassium
NCT03684993PHASE2/PHASE3COMPLETEDCaries Prevention and Side Effects of Gum Arabic and Licorice Extracts Versus Chlorhexidine in High Caries Risk Patients
NCT02453503PHASE2COMPLETEDComparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on Lichen Planus
NCT03948243PHASE1COMPLETEDLicorice Botanical Dietary Supplements - Metabolism and Safety in Women
NCT01444703Not specifiedCOMPLETEDComparison of Licorice Versus Sugar-water Gargle for Prevention of Postoperative Sore Throat and Postextubation Coughing
NCT02968823Not specifiedCOMPLETEDLicorice Versus Sugar-water Gargling for Pain in Patients Recovering From Ear-Nose-Throat and Maxilla-Facial Surgery
NCT03550651Not specifiedCOMPLETEDEvaluation of Antiplaque Efficacy of Licorice Extract Mouthrinse & HSS and Their Comparison With EO & CHX Mouthrinse
NCT03763578Not specifiedCOMPLETEDDental Caries Prevention by a Natural Product
NCT04487964Not specifiedCOMPLETEDComplementary Intervention for COVID-19
NCT05661721Not specifiedCOMPLETEDLicorice and Home Blood Pressure
NCT06019598Not specifiedCOMPLETEDLicorice and Home Blood Pressure, Additional Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.